Page 2 - Masahiro Tsuboi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TAGRISSO® (osimertinib) demonstrated 5 5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer

Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease

United kingdomLe chevalierProvence alpes côd azurUnited statesFrance generalMasahiro tsuboiDaiichi sankyoThorac oncSusan galbraithNational cancer center hospitalCollaborative groupSingle institution studyData monitoring committeeLung ambition allianceArchivespathology labWorld health organisation

Tagrisso demonstrated 5 5-year median disease-free survival in adjuvant treatment of patients with EGFR-mutated lung cancer

Tagrisso demonstrated 5 5-year median disease-free survival in adjuvant treatment of patients with EGFR-mutated lung cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

France generalMasahiro tsuboiAstrazeneca tagrissoSusan galbraithNational cancer center hospitalEuropean society for medical oncologyDepartment of thoracic surgery oncologyEuropean societyMedical oncologyThoracic surgeryNational cancer center hospital eastExecutive vice president

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso approved in Japan for early lung cancer

Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer

United statesUnited kingdomDave fredricksonMasahiro tsuboiDaiichi sankyoThorac oncAstrazeneca tagrissoAdrian kempLe chevalierCompany on twitterInternational agency for research on cancerDepartment of thoracic surgery oncologyNational cancer center hospitalCollaborative groupSingle institution studyArchives pathology lab

Survival Boost With Neoadjuvant Chemo-Immunotherapy in NSCLC

Adding neoadjuvant nivolumab to chemotherapy in stage IIIA/IIIB non¬–small cell lung cancer markedly improves both progression-free and overall survival over neoadjuvant chemotherapy alone.

United statesUnited kingdomMariano provencioWestdeutsches tumorzentrum essenMasahiro tsuboiWilfried eberhardtIsabelle opitzSalud carlosCorinne faivre finnEuropean union horizonNational cancer center hospitalDepartment of thoracic surgeryUniversity hospital zurichAmerican society of clinical oncologyUniversity of manchesterBoehringer ingelheim